Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by Eventide Asset Management LLC

Eventide Asset Management LLC lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 507,902 shares of the company’s stock after acquiring an additional 45,803 shares during the quarter. Eventide Asset Management LLC’s holdings in Kymera Therapeutics were worth $24,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Values First Advisors Inc. acquired a new position in Kymera Therapeutics during the third quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. grew its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the period. Comerica Bank grew its position in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the period. Public Employees Retirement Association of Colorado acquired a new position in Kymera Therapeutics during the second quarter worth about $139,000. Finally, Quest Partners LLC grew its position in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after buying an additional 4,865 shares during the period.

Insider Transactions at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Morgan Stanley increased their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Oppenheimer increased their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Truist Financial reiterated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.13.

Kymera Therapeutics Stock Up 1.9 %

NASDAQ:KYMR opened at $46.86 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.11 and a fifty-two week high of $53.27. The firm’s 50 day moving average is $46.88 and its two-hundred day moving average is $42.11.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.90) earnings per share. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.